Farvardin Mohsen, Eghtedari Dorna, Shahmohammadi Maryam, Johari Mohammadkarim
Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Int J Retina Vitreous. 2025 Mar 18;11(1):32. doi: 10.1186/s40942-025-00657-6.
To compare the efficacy and safety of half-dose and one-third-dose photodynamic therapy (PDT) with verteporfin in patients with chronic central serous chorioretinopathy (CSC).
This retrospective study included 72 eyes from 72 patients with chronic CSC treated with either one-third-dose (2 mg/m²) or half-dose (3 mg/m²) PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), subretinal fluid (SRF) thickness, subfoveal choroidal thickness (SFCT), and optical coherence tomography (OCT) features were evaluated at baseline, 3 months, and 12 months. Fluorescein angiography (FA) was used to guide laser application. Treatment outcomes, including SRF resolution, BCVA gain, and recurrence rates, were compared between the two groups.
At 12 months, complete SRF resolution was achieved in 40 eyes (78.4%) in the half-dose group and 15 eyes (71.4%) in the one-third-dose group. The recurrence rate of SRF was significantly higher in the one-third-dose group (20%) compared to the half-dose group (7.5%) (P =.015). BCVA improved significantly in both groups, with mean increases from 72.4 ± 3.9 to 77.1 ± 5.6 letters in the one-third-dose group and from 74.4 ± 4.2 to 80.2 ± 2.19 letters in the half-dose group. The proportion of patients achieving a ≥ 10-letter gain was higher in the half-dose group (52%) compared to the one-third-dose group (28.5%, P =.001). Both groups exhibited significant reductions in CRT, SRF thickness, and SFCT (P <.001), with no significant intergroup differences. Baseline CRT and fluorescein leakage patterns influenced treatment response.
Both one-third-dose and half-dose PDT effectively improved visual and anatomical outcomes in patients with chronic CSC. However, half-dose PDT demonstrated superior efficacy in achieving SRF resolution and greater visual acuity gains with a lower recurrence rate.
Not applicable.
比较半剂量和三分之一剂量维替泊芬光动力疗法（PDT）治疗慢性中心性浆液性脉络膜视网膜病变（CSC）患者的疗效和安全性。
这项回顾性研究纳入了72例慢性CSC患者的72只眼，这些患者接受了三分之一剂量（2mg/m²）或半剂量（3mg/m²）的PDT治疗。在基线、3个月和12个月时评估最佳矫正视力（BCVA）、视网膜中央厚度（CRT）、视网膜下液（SRF）厚度、黄斑中心凹下脉络膜厚度（SFCT）以及光学相干断层扫描（OCT）特征。使用荧光素血管造影（FA）来指导激光应用。比较两组的治疗结果，包括SRF消退、BCVA提高和复发率。
在12个月时，半剂量组40只眼（78.4%）实现了SRF完全消退，三分之一剂量组15只眼（71.4%）实现了SRF完全消退。三分之一剂量组SRF的复发率（20%）显著高于半剂量组（7.5%）（P = 0.015）。两组的BCVA均有显著改善，三分之一剂量组平均从72.4±3.9提高到77.1±5.6个字母，半剂量组平均从74.4±4.2提高到80.2±2.19个字母。半剂量组实现≥10个字母提高的患者比例（52%）高于三分之一剂量组（28.5%，P = 0.001）。两组的CRT、SRF厚度和SFCT均显著降低（P < 0.001），组间无显著差异。基线CRT和荧光素渗漏模式影响治疗反应。
三分之一剂量和半剂量的PDT均能有效改善慢性CSC患者的视力和解剖学结果。然而，半剂量PDT在实现SRF消退和提高视力方面显示出更好的疗效，且复发率更低。
不适用。
Zotero 插件
